TMCnet

Keys Inc. Files U.S. Provisional Patent Application for Autonomous AI Infrastructure Redefining On-Demand Service Networks

TUCSON, Ariz., March 2, 2026 /PRNewswire/ -- Keys Inc. today announced the filing of U.S. Provisional Patent Application No.
Nasdaq

Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative ...
Nasdaq

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications The provisional patent application describes novel nanoparticle ...
Morningstar

LegalZoom Launches Streamlined Provisional Patent Filing Product to Help Businesses and Entrepreneurs Protect Intellectual Property, Secure Funding and Drive Growth

LegalZoom Launches Streamlined Provisional Patent Filing Product to Help Businesses and Entrepreneurs Protect Intellectual Property, Secure Funding and Drive Growth LegalZoom’s law firm to provide ...
Seeking Alpha

Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (RAPH), a clinical-stage biotechnology company developing an innovative research platform based on cannabinoids free of THC and ...
Seeking Alpha

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd.